TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2025

Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial.

Nigel H Russell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.